Compare WTTR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTTR | IVA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | France |
| Employees | N/A | 84 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2017 | N/A |
| Metric | WTTR | IVA |
|---|---|---|
| Price | $14.01 | $5.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $16.17 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 1.8M | 315.6K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,528,930,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $69.16 | ★ N/A |
| Revenue Growth | ★ 120.79 | N/A |
| 52 Week Low | $7.20 | $2.70 |
| 52 Week High | $15.45 | $7.98 |
| Indicator | WTTR | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 43.83 |
| Support Level | $10.10 | $5.79 |
| Resistance Level | $14.24 | $6.48 |
| Average True Range (ATR) | 0.54 | 0.30 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 85.33 | 9.70 |
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.